Piper Jaffray Starts CRISPR Therapeutics (CRSP) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St steadies ahead of South Korean chip bellwether SK Hynix's debut
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- The real reason Meta shares are surging has nothing to do with its new AI model
Citi Starts CRISPR Therapeutics (CRSP) at Neutral
November 15, 2016 7:41 AM ESTCiti initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Neutral rating and a price target of $19.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.60 yesterday.
... MoreGuggenheim Starts CRISPR Therapeutics (CRSP) at Buy
November 14, 2016 7:56 AM ESTGuggenheim initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.50 yesterday.
... More